ABN201 is an antibody cytokine fusion protein(ACFP) which adds antibody targeting ability to ABN101 with effective anticancer activity. It has a potential to be developed as an anticancer platform with greater application than ADC. ABN201 is targeting solid cancer and combination therapy with ABN401 and EGFR inhibitors are being studied.
Direct Cytotoxicity
- IFNb localization to tumor
- Direct tumor cell killing through IFN-receptor induced death receptor mediated apoptosis
Indirect Cytotoxicity
- Tumor derived antigen cross-presentation of CD8α+ DC, stimulated by IFNb
- Activation of antigen-specific cytotoxic T-cell
- Tumor cell death
